Company profile: Immunocore
1.1 - Company Overview
Company description
- Provider of T cell receptor (TCR) bispecific immunotherapies. Offers KIMMTRAK, approved for HLA-A*02:01-positive adult patients with unresectable or metastatic uveal melanoma in various regions including the US and EU. Leverages the ImmTAX platform to develop TCR therapies that activate the immune system to target infected or tumor cells or reduce autoimmune responses, with a clinical pipeline in solid tumors, infectious and autoimmune diseases.
Products and services
- Clinical pipeline: Clinical-stage portfolio of TCR bispecific therapeutics for solid tumors, infectious diseases, and autoimmune conditions, applying ImmTAX-mediated immune activation or immune modulation across multiple investigational programs
- ImmTAX technology: Modular platform that engineers TCR bispecific assemblies by fusing optimized TCRs to anti‑CD3 scFv, either activating T cells against tumor/infected cells or reducing autoimmune responses
- KIMMTRAK: FDA/EMA-approved TCR bispecific drug linking an engineered TCR to anti‑CD3 scFv to treat HLA-A*02:01-positive adult patients with unresectable or metastatic uveal melanoma
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to Immunocore
MabVax Therapeutics
HQ: United States
Website
- Description: Provider of proprietary anti-cancer immunotherapies as a biopharmaceutical company focused on their commercialization.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full MabVax Therapeutics company profile →
Trethera
HQ: United States
Website
- Description: Provider of small-molecule therapeutics that control DNA replication and integrity, including TRE-515, an orally bioavailable inhibitor of deoxycytidine kinase (dCK) targeting the nucleotide salvage pathway to treat solid tumors and autoimmune diseases.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Trethera company profile →
Nerio Therapeutics
HQ: United States
Website
- Description: Provider of biotechnology for the life sciences sector; founded in 2019 and based in La Jolla, CA, USA.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Nerio Therapeutics company profile →
Indi
HQ: United States
Website
- Description: Provider of diagnostic products leveraging emerging technologies to help physicians and patients diagnose and manage complex diseases, such as cancer, diabetes, and Alzheimer’s, through non-invasive blood tests that monitor tens to hundreds of disease markers simultaneously.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Indi company profile →
OxSonics Therapeutics
HQ: United Kingdom
Website
- Description: Provider of a proprietary ultrasound-enabled drug delivery platform, SonoTran, designed to enhance penetration and distribution of anti-cancer agents within solid tumors. Offerings include SonoTran Particles with stabilised gas bubbles for cavitation, the SonoTran System for imaging, treatment and monitoring, a development pipeline with oncology drugs, and partnering services for pharmaceutical and biotech companies.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full OxSonics Therapeutics company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for Immunocore
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to Immunocore
2.2 - Growth funds investing in similar companies to Immunocore
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for Immunocore
4.2 - Public trading comparable groups for Immunocore
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →